❌

Reading view

Vision-DeepResearch: Incentivizing DeepResearch Capability in Multimodal Large Language Models

arXiv:2601.22060v3 Announce Type: replace-cross Abstract: Multimodal large language models (MLLMs) have achieved remarkable success across a broad range of vision tasks. However, constrained by the capacity of their internal world knowledge, prior work has proposed augmenting MLLMs by ``reasoning-then-tool-call'' for visual and textual search engines to obtain substantial gains on tasks requiring extensive factual information. However, these approaches typically define multimodal search in a naive setting, assuming that a single full-level or entity-level image query and few text query suffices to retrieve the key evidence needed to answer the question, which is unrealistic in real-world scenarios with substantial visual noise. Moreover, they are often limited in the reasoning depth and search breadth, making it difficult to solve complex questions that require aggregating evidence from diverse visual and textual sources. Building on this, we propose Vision-DeepResearch, which proposes one new multimodal deep-research paradigm, i.e., performs multi-turn, multi-entity and multi-scale visual and textual search to robustly hit real-world search engines under heavy noise. Our Vision-DeepResearch supports dozens of reasoning steps and hundreds of engine interactions, while internalizing deep-research capabilities into the MLLM via cold-start supervision and RL training, resulting in a strong end-to-end multimodal deep-research MLLM. It substantially outperforming existing multimodal deep-research MLLMs, and workflows built on strong closed-source foundation model such as GPT-5, Gemini-2.5-pro and Claude-4-Sonnet. The code will be released in https://github.com/Osilly/Vision-DeepResearch.
  •  

The Current Landscape of Remote Digital Symptom Monitoring for Patients With Lung Cancer: Scoping Review

Background: Remote digital symptom monitoring systems (rSMS) have been increasingly used in recent years to monitor symptoms, health-related quality of life, and other patient-reported outcomes in lung cancer. Previous studies have demonstrated variability in study design, types of rSMS, and outcomes used to assess benefits for patients and health care systems. However, there remains a lack of synthesized evidence pertaining to the similarities and differences among rSMS, including their theoretical underpinnings, key functional components, and reported benefits and limitations. Objective: This review aims to identify and synthesize existing research to map the current landscape of rSMS in lung cancer, including the theoretical foundations for its development and implementation, as well as its types, applications, and outcomes. Methods: This scoping review followed the Joanna Briggs Institute scoping review framework and adhered to the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews) guidelines. A comprehensive literature search was conducted from database inception to October 16, 2025, across 7 English-language databases and 3 Chinese-language databases (CNKI, WanFang, and SinoMed). Eligible studies were peer-reviewed original research articles examining rSMS among adults with lung cancer. Data were independently screened and extracted by 2 reviewers, with discrepancies resolved by a third reviewer. Quantitative data were extracted using a standardized form and synthesized descriptively. Content analysis was performed to analyze the qualitative data. Results: A total of 41 studies involving 11,765 patients and 85 health care providers were included. Twelve studies focused exclusively on advanced-stage lung cancer. Participants were generally middle-aged to older adults (mean ages 51‐74 y), with male participants typically comprising 30% to 50% across studies. Most studies were conducted in the United States (n=19). We identified 32 patient-reported outcome measures that were used either as core rSMS components or as study outcomes. Four common functional modules were observed across rSMS: data collection, data analysis, response systems, and patient education. Qualitative evidence was limited; the most frequently reported benefit was the promotion of patient-centered care. Health care providers raised concerns about uncertain effectiveness and increased workload. Conclusions: This scoping review highlights the promising role of rSMS in lung cancer care and provides a structured map of current evidence. It adds to prior literature in 3 ways. First, it summarizes how and how often theoretical frameworks are reported and applied in rSMS development and implementation. Second, it synthesizes and categorizes four common functional modules across systems. Third, it differentiates measures embedded as rSMS components from those used as evaluation outcomes. These contributions clarify current practices and methodological gaps and underscore the importance of theory-informed design, functional clarity, and stakeholder engagement in the development of patient-centered, clinically meaningful, and sustainable rSMS platforms. Trial Registration: OSF Registries 9637t; https://osf.io/9637t/overview
  •  

Effects of multisensory stimulation based on immersive virtual reality in postoperative neuropsychiatric recovery after gynecological laparoscopy

npj Digital Medicine, Published online: 24 March 2026; doi:10.1038/s41746-026-02515-7

Effects of multisensory stimulation based on immersive virtual reality in postoperative neuropsychiatric recovery after gynecological laparoscopy
  •  

Deciphering lung adenocarcinoma heterogeneity: a multi-omics approach reveals nuclear division fibroblasts as prognosticators and therapeutic targets

J Transl Med. 2026 Mar 20. doi: 10.1186/s12967-026-08022-3. Online ahead of print.

ABSTRACT

BACKGROUND: Lung adenocarcinoma (LUAD) is a predominant contributor to cancer‑related mortality globally. Lung‑associated fibroblasts (LAFs) are intricately linked to tumorigenesis and the tumor microenvironment (TME), but their heterogeneity and prognostic relevance in LUAD remain incompletely understood. This study aimed to systematically characterize LAF subsets across the spectrum of pulmonary disease, identify LAF subpopulations associated with LUAD prognosis, and construct a robust LAF‑based prognostic signature.

METHODS: We employed a multi-omics approach, leveraging bulk RNA data of 2719 patients from 19 LUAD cohorts, single-cell RNA (scRNA) sequencing data of 368,904 cells from 93 samples, and spatial transcriptomics data of 15,673 spots from 6 samples to characterize the landscape of LAFs across various stages of pulmonary disease. We employed multiple advanced machine learning algorithms to construct and validate a robust nuclear division LAFs (nLAFs) risk score (nLRS) prediction model.

RESULTS: We observed a dynamic and gradual increase in the proportion of LAFs during the progression of LUAD. Throughout this process, we identified nine LAFs subtypes and found nLAFs are significantly associated with the prognosis of LUAD. Utilizing 100 machine learning algorithm combinations and integrating nLAFs marker genes, we developed a five gene based nLRS model, which demonstrated superior performance than other 49 published models in predicting clinical outcomes for LUAD. Additionally, we observed distinct biological functions and immune cell infiltration in the TME between high and low nLRS groups. Exploratory analysis of pan-cancer immunotherapy cohorts suggested that patients with high nLRS scores may exhibit resistance to immunotherapy in some cancer types, but prospective validation in LUAD-specific cohorts is required. Conversely, high nLRS patients displayed increased sensitivity to chemotherapeutic and targeted therapies in preclinical models.

CONCLUSION: Our study introduces a candidate five-gene signature derived from nLAFs that may serve as a robust prognostic biomarker pending prospective validation, offering insights into personalized therapeutic strategies for LUAD patients.

PMID:41862916 | DOI:10.1186/s12967-026-08022-3

  •  
❌